Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

NCT06717815 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis

Interventions

DRUG: IPG11406

Sponsor

Nanjing Immunophage Biotech Co., Ltd